**Core Concept:** Lignocaine toxicity is a potential complication of administering the local anesthetic drug lignocaine. The correct management involves neutralizing the toxic effects of lignocaine and supporting the patient's vital functions.

**Why the Correct Answer is Right:** The correct answer is **D:** **Flumazenil**. Flumazenil is a specific antagonist for benzodiazepines, which are a class of drugs that lignocaine mimics in its toxic effects. In lignocaine toxicity, patients may present with seizures, respiratory depression, and cardiovascular collapse due to the enhancement of gamma-aminobutyric acid (GABA) receptors by lignocaine. Flumazenil can counteract these effects by binding to benzodiazepine receptors and blocking the lignocaine-induced enhancement of GABA activity.

**Why Each Wrong Option is Incorrect:**

A. **Epinephrine:** Epinephrine is a vasoconstrictor and has no direct role in managing lignocaine toxicity, which is primarily due to the effects of lignocaine on GABA receptors.

B. **Naloxone:** Naloxone is a specific antagonist for opioids, which is not involved in lignocaine toxicity.

C. **Sodium bicarbonate:** Sodium bicarbonate is used to correct hypokalemia and alkalinize the blood pH in lignocaine-induced acidosis. However, it does not address the GABA receptor enhancement caused by lignocaine.

**Clinical Pearl:** In lignocaine toxicity, it is crucial to recognize the clinical presentation promptly and initiate specific treatment with flumazenil to prevent further complications and improve patient outcomes.

**Correct Answer:**

**Correct Answer: D. Flumazenil**

Flumazenil is the appropriate choice to counteract the toxic effects of lignocaine on GABA receptors and restore the balance of inhibitory and excitatory neurotransmitters in the central nervous system. This can help stabilize the patient's vital signs and prevent further complications associated with lignocaine toxicity.